Therapy for kerions was evaluated by randomly assigning 30 patients to one of four treatment groups: group A griseofulvin, group B griseofulvin plus erythromycin, group C griseofulvin plus prednisone, and group D griseofulvin, erythromycin, and prednisone. Data indicate that antibiotic and steroid therapy, in addition to griseofulvin, may reduce scaling and pruritus, but does not reduce the time it takes for kerions to flatten.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1525-1470.1994.tb00079.xDOI Listing

Publication Analysis

Top Keywords

group griseofulvin
16
griseofulvin erythromycin
8
griseofulvin
5
treatment kerions
4
kerions therapy
4
therapy kerions
4
kerions evaluated
4
evaluated randomly
4
randomly assigning
4
assigning patients
4

Similar Publications

Article Synopsis
  • The Indian Coffee Plum (Flacourtia jangomas) is a medicinal plant known for its bioactive compounds and potential therapeutic benefits, prompting research into its extracts from bark for medical applications.
  • The study involved extracting phytochemicals using methanol, conducting screenings, and comparing the biological activities of the extracts, revealing the presence of new compounds like methyl caffeate and flacourtin.
  • Results showed the extract has strong antioxidant and cytotoxic properties, pain relief effects, and moderate thrombolytic action, but limited antibacterial and antifungal activities, indicating a need for further research on its bioactive compounds.
View Article and Find Full Text PDF

and the recently separated acremonium-like genera, such as , are emerging causes of opportunistic disease in humans, mainly post-traumatic infections in immunocompetent hosts, but also invasive infections in immunocompromised patients, such as those undergoing transplantation. has emerged as the major pathogenic species in humans, implicated mainly in nail but also in disseminated and organ specific infections. In this first study of acremonium-like clinical isolates in Greece, 34 isolates were identified and typed by sequencing the internal transcribed spacer, and their antifungal susceptibility was determined by a modified CLSI standard M38 3rd Edition method for filamentous fungi.

View Article and Find Full Text PDF

Long-acting injectable (LAI) cabotegravir and rilpivirine for HIV treatment and LAI cabotegravir for pre-exposure HIV prophylaxis are being rolled out in a multitude of countries worldwide. Due to the prolonged exposure, it can be challenging to undertake 'traditional' pharmacokinetic studies and current guidance is derived from their oral equivalents or physiologically based pharmacokinetic studies. This review aims to consider pharmacokinetic characteristics of cabotegravir and rilpivirine and describe anticipated drug-drug interactions (DDIs) with frequent concomitant medications in African settings.

View Article and Find Full Text PDF

Efficacy of antimalarials in oral lichen planus: A systematic review.

Oral Dis

October 2024

Department of Dental Clinical Specialties, ORALMED Research Group, School of Dentistry, Complutense University, Madrid, Spain.

Objective: To evaluate whether hydroxychloroquine (HCQ) or chloroquine (CQ) are effective for the treatment of oral lichen planus (OLP).

Materials And Methods: A literature search was conducted in four databases. Clinical studies investigating the effect of HCQ/CQ in patients with OLP were included.

View Article and Find Full Text PDF

Context: Warfarin is extensively used for venous thromboembolism and other coagulopathies. In clinical settings, warfarin is administered as a mixture of S-warfarin and R-warfarin, and both enantiomers are metabolized by multiple cytochrome P450 enzymes into many hydroxylation metabolites. Validation of analysis method and estimation of warfarin plasma levels are important, especially in narrow-index drugs such as warfarin.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!